There is no approved vaccine for this strain, which has killed more than 5,000 people in Congo since May.
BLACKOUT.NETWORK desk brief, written Nov 12, 5:58 PM EST from the sources listed below.
01What happened
Expert groups convened by WHO recommended adding two vaccine candidates to the Tumaini clinical trial in Congo, WHO said on Nov. 4: Oxford and the Serum Institute of India's ChAdOx1, and Moderna's mRNA-1469. WHO says it is the first time vaccines designed specifically for Bundibugyo virus will be tested during an outbreak of it. At the time, the US CDC counted 10,699 cases and 5,202 deaths, CIDRAP reported.
02Why it matters
The candidates join the trial after the approvals WHO describes. Testing during an outbreak is the fastest way to learn whether a vaccine works, but results will take time. Meanwhile MSF is pushing for wider use of the existing Ervebo vaccine, which targets a different strain.
- It is one of 2 related disease and outbreaks stories on our board in the past 7 days.
Related: "With the number of confirmed cases now surpassing 11,000, the outbreak — declared in…
03Why we ranked it this way
- Our read: WHO's own announcement plus CIDRAP and European CDC data; a 5, Significant, fits a step forward in the response.
- 5/10, Significant. That is our level for stories whose reach is regional / national.
- Confirmation: Confirmed by official sources (CIDRAP News). This rank needs: official source, or 2+ independent sources.
Rank 5 of 10 · Significant
- Rank
- 5/10
- Significant
- Independent sources
- 1
- Official sources
- 1
- Reports logged
- 1
Built from the reports BLACKOUT.NETWORK logged for this story. Rank rules: How we score.
04Risk factor
Risk·Medium
LowMediumHighOur analysts rate this medium: The outbreak is serious, but this news is a step forward and poses no new risk.
05If it’s true, if it’s overblown
If it’s true
If the trial vaccines work, they could be used to protect health workers and contacts in this and future outbreaks.
If it’s overblown
If they fail or are delayed, the response relies on tracing, isolation and possibly wider use of Ervebo. Our confidence in the reporting is high: WHO's official announcement, CIDRAP and the European CDC.
06What you should do
- No action is needed.